MT1-MMP sheds LYVE-1 on lymphatic endothelial cells and suppresses VEGF-C production to inhibit lymphangiogenesis

Nature Communications

Volumn 7, Issue , 2016, Pages

  Wong, Hoi Leong Xavier ^a,b   Jin, Guoxiang ^b   Cao, Renhai ^c   Zhang, Shuo ^a,b   Cao, Yihai ^c   Zhou, Zhongjun ^a,b  

^a UNIVERSITY OF HONG KONG   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

HERMES ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MATRIX METALLOPROTEINASE 14; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; VASCULOTROPIN C; GLYCOPROTEIN; MMP14 PROTEIN, MOUSE; VASCULAR ENDOTHELIAL GROWTH FACTOR C, MOUSE; XLKD1 PROTEIN, MOUSE;

CANCER; CELLS AND CELL COMPONENTS; GENE; GENE EXPRESSION; INHIBITOR; MEMBRANE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW DERIVED MACROPHAGE; CATALYSIS; CELL SURFACE; CONTROLLED STUDY; CORNEA; CYTOKINE PRODUCTION; LYMPH VESSEL; LYMPH VESSEL ENDOTHELIUM; LYMPHANGIOGENESIS; MACROPHAGE; MOUSE; NONHUMAN; PHENOTYPE; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; UPREGULATION; WESTERN BLOTTING; ANIMAL; BONE TRANSPLANTATION; CELL CULTURE; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; GENETICS; KNOCKOUT MOUSE; METABOLISM; PHYSIOLOGY;

MUS;

ANIMALS; BONE TRANSPLANTATION; CELLS, CULTURED; CORNEA; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION; GLYCOPROTEINS; LYMPHANGIOGENESIS; MACROPHAGES; MATRIX METALLOPROTEINASE 14; MICE; MICE, KNOCKOUT; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 84959451851     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms10824     Document Type: Article

References (61)

1. Tammela, T. & Alitalo, K. Lymphangiogenesis: molecular mechanisms and future promise. Cell 140, 460-476 (2010).
2. Achen, M. G. & Stacker, S. A. Molecular control of lymphatic metastasis. Ann. N. Y. Acad. Sci. 1131, 225-234 (2008).
3. Stacker, S. A. et al. Lymphangiogenesis and lymphatic vessel remodelling in cancer. Nat. Rev. Cancer 14, 159-172 (2014).
4. Banerji, S. et al. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J. Cell Biol. 144, 789-801 (1999).
5. Wu, M. et al. Low molecular weight hyaluronan induces lymphangiogenesis through LYVE-1-mediated signaling pathways. PLoS ONE 9, e92857 (2014).
6. Karkkainen, M. J. et al. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat. Immunol. 5, 74-80 (2004).
7. Yoon, Y. S. et al. VEGF-C gene therapy augments postnatal lymphangiogenesis and ameliorates secondary lymphedema. J. Clin. Invest. 111, 717-725 (2003).
8. Veikkola, T. et al. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J. 20, 1223-1231 (2001).
9. Cao, R. et al. Collaborative interplay between FGF-2 and VEGF-C promotes lymphangiogenesis and metastasis. Proc. Natl Acad. Sci. USA 109, 15894-15899 (2012).
10. Cao, R. et al. Mouse corneal lymphangiogenesis model. Nat. Protoc. 6, 817-826 (2011).
11. Joukov, V. et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 15, 1751 (1996).
12. Kukk, E. et al. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development 122, 3829-3837 (1996).
13. Achen, M. G. et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc. Natl Acad. Sci. USA 95, 548-553 (1998).
14. Barbolina, M. V. & Stack, M. S. Membrane type 1-matrix metalloproteinase: substrate diversity in pericellular proteolysis. Semin. Cell Dev. Biol. 19, 24-33 (2008).
15. Holmbeck, K. et al. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 99, 81-92 (1999).
16. Chan, K. M. et al. MT1-MMP inactivates ADAM9 to regulate FGFR2 signaling and calvarial osteogenesis. Dev. Cell 22, 1176-1190 (2012).
17. Zhou, Z. et al. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc. Natl Acad. Sci. USA 97, 4052-4057 (2000).
18. Chun, T. H. et al. A pericellular collagenase directs the 3-dimensional development of white adipose tissue. Cell 125, 577-591 (2006).
19. Jin, G. et al. MT1-MMP cleaves Dll1 to negatively regulate Notch signalling to maintain normal B-cell development. EMBO J. 30, 2281-2293 (2011).
20. Nishida, C. et al. MT1-MMP plays a critical role in hematopoiesis by regulating HIF-mediated chemokine/cytokine gene transcription within niche cells. Blood 119, 5405-5416 (2012).
21. Evans, B. R. et al. Mutation of membrane type-1 metalloproteinase, MT1-MMP, causes the multicentric osteolysis and arthritis disease Winchester syndrome. Am. J. Hum. Genet. 91, 572-576 (2012).
22. Wong, H. L. et al. When MT1-MMP meets ADAMs. Cell Cycle 11, 2793-2798 (2012).
23. Koziol, A. et al. The protease MT1-MMP drives a combinatorial proteolytic program in activated endothelial cells. FASEB J. 26, 4481-4494 (2012).
24. Schledzewski, K. et al. Lymphatic endothelium-specific hyaluronan receptor LYVE-1 is expressed by stabilin-1+, F4/80+, CD11b+ macrophages in malignant tumours and wound healing tissue in vivo and in bone marrow cultures in vitro: implications for the assessment of lymphangiogenesis. J. Pathol. 209, 67-77 (2006).
25. Kumar, S., Ratnikov, B. I., Kazanov, M. D., Smith, J. W. & Cieplak, P. Correction: CleavPredict: a platform for reasoning about matrix metalloproteinases proteolytic events. PLoS ONE 10, e0131952 (2015).
26. Platonova, N. et al. Evidence for the interaction of fibroblast growth factor-2 with the lymphatic endothelial cell marker LYVE-1. Blood 121, 1229-1237 (2013).
27. Bourguignon, L. Y., Singleton, P. A., Zhu, H. & Diedrich, F. Hyaluronanmediated CD44 interaction with RhoGEF and Rho kinase promotes Grb2-associated binder-1 phosphorylation and phosphatidylinositol 3-kinase signaling leading to cytokine (macrophage-colony stimulating factor) production and breast tumor progression. J. Biol. Chem. 278, 29420-29434 (2003).
28. Maruyama, K. et al. Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages. J. Clin. Invest. 115, 2363-2372 (2005).
29. Cursiefen, C. et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J. Clin. Invest. 113, 1040-1050 (2004).
30. Kataru, R. P. et al. Critical role of CD11b+ macrophages and VEGF in inflammatory lymphangiogenesis, antigen clearance, and inflammation resolution. Blood 113, 5650-5659 (2009).
31. Schoppmann, S. F. et al. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am. J. Pathol. 161, 947-956 (2002).
32. Watari, K. et al. Role of macrophages in inflammatory lymphangiogenesis: enhanced production of vascular endothelial growth factor C and D through NF-kappaB activation. Biochem. Biophys. Res. Commun. 377, 826-831 (2008).
33. Zumsteg, A. et al. Myeloid cells contribute to tumor lymphangiogenesis. PLoS ONE 4, e7067 (2009).
34. Shimizu-Hirota, R. et al. MT1-MMP regulates the PI3Kdelta. Mi-2/NuRDdependent control of macrophage immune function. Genes Dev. 26, 395-413 (2012).
35. Hall, K. L., Volk-Draper, L. D., Flister, M. J. & Ran, S. New model of macrophage acquisition of the lymphatic endothelial phenotype. PLoS ONE 7, e31794 (2012).
36. Zhang, Y. et al. Activation of vascular endothelial growth factor receptor-3 in macrophages restrains TLR4-NF-kappaB signaling and protects against endotoxin shock. Immunity 40, 501-514 (2014).
37. Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M. & Bilanges, B. The emerging mechanisms of isoform-specific PI3K signalling. Nat. Rev. Mol. Cell Biol. 11, 329-341 (2010).
38. Dinarello, C. A. Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol. 27, 519-550 (2009).
39. Aksoy, E. et al. The p110delta isoform of the kinase PI(3)K controls the subcellular compartmentalization of TLR4 signaling and protects from endotoxic shock. Nat. Immunol. 13, 1045-1054 (2012).
40. Zhang, Q. et al. VEGF-C, a lymphatic growth factor, is a RANKL target gene in osteoclasts that enhances osteoclastic bone resorption through an autocrine mechanism. J. Biol. Chem. 283, 13491-13499 (2008).
41. Vallabhapurapu, S. & Karin, M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu. Rev. Immunol. 27, 693-733 (2009).
42. Gale, N. W. et al. Normal lymphatic development and function in mice deficient for the lymphatic hyaluronan receptor LYVE-1. Mol. Cell. Biol. 27, 595-604 (2007).
43. Protin, U., Schweighoffer, T., Jochum, W. & Hilberg, F. CD44-deficient mice develop normally with changes in subpopulations and recirculation of lymphocyte subsets. J. Immunol. 163, 4917-4923 (1999).
44. Zoller, M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat. Rev. Cancer 11, 254-267 (2011).
45. Wei, Q. et al. CD82 restrains pathological angiogenesis by altering lipid raft clustering and CD44 trafficking in endothelial cells. Circulation 130, 1493-1504 (2014).
46. Prevo, R., Banerji, S., Ferguson, D. J., Clasper, S. & Jackson, D. G. Mouse LYVE-1 is an endocytic receptor for hyaluronan in lymphatic endothelium. J. Biol. Chem. 276, 19420-19430 (2001).
47. Ingvarsen, S. et al. Targeting a single function of the multifunctional matrix metalloprotease MT1-MMP: impact on lymphangiogenesis. J. Biol. Chem. 288, 10195-10204 (2013).
48. Detry, B. et al. Matrix metalloproteinase-2 governs lymphatic vessel formation as an interstitial collagenase. Blood 119, 5048-5056 (2012).
49. Albuquerque, R. J. et al. Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. Nat. Med. 15, 1023-1030 (2009).
50. Singh, N. et al. Soluble vascular endothelial growth factor receptor-3 is essential for corneal alymphaticity. Blood 121, 4242-4249 (2013).
51. Baluk, P. et al. TNF-alpha drives remodeling of blood vessels and lymphatics in sustained airway inflammation in mice. J. Clin. Invest. 119, 2954-2964 (2009).
52. Kubota, Y. et al. M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis. J. Exp. Med. 206, 1089-1102 (2009).
53. Brissette-Storkus, C. S., Reynolds, S. M., Lepisto, A. J. & Hendricks, R. L. Identification of a novel macrophage population in the normal mouse corneal stroma. Invest. Ophthalmol. Vis. Sci. 43, 2264-2271 (2002).
54. Merline, R. et al. Signaling by the matrix proteoglycan decorin controls inflammation and cancer through PDCD4 and MicroRNA-21. Sci. Signal. 4, ra75 (2011).
55. Funderburgh, J. L. et al. Decorin and biglycan of normal and pathologic human corneas. Invest. Ophthalmol. Vis. Sci. 39, 1957-1964 (1998).
56. Mohan, R. R., Tovey, J. C., Gupta, R., Sharma, A. & Tandon, A. Decorin biology, expression, function and therapy in the cornea. Curr. Mol. Med. 11, 110-128 (2011).
57. Ji, H. et al. TNFR1 mediates TNF-alpha-induced tumour lymphangiogenesis and metastasis by modulating VEGF-C-VEGFR3 signalling. Nat. Commun. 5, 4944 (2014).
58. Egeblad, M. & Werb, Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2, 161-174 (2002).
59. An, N. & Kang, Y. Using quantitative real-time PCR to determine donor cell engraftment in a competitive murine bone marrow transplantation model. J. Vis. Exp. 73, e50193 (2013).
60. Pitulescu, M. E., Schmidt, I., Benedito, R. & Adams, R. H. Inducible gene targeting in the neonatal vasculature and analysis of retinal angiogenesis in mice. Nat. Protoc. 5, 1518-1534 (2010).
61. Krishnan, V. et al. Histone H4 lysine 16 hypoacetylation is associated with defective DNA repair and premature senescence in Zmpste24-deficient mice. Proc. Natl Acad. Sci. USA 108, 12325-12330 (2011).